INTRODUCTION:

Crohn’s Disease (CD) and Ulcerative Colitis (UC) are the two primary forms of Inflammatory Bowel Disease (IBD), both characterized by chronic inflammation of the gastrointestinal (GI) tract. Although the precise cause remains unclear, a combination of genetic, environmental, and immune-related factors is believed to trigger an abnormal immune response, leading to inflammation in the intestinal lining. CD can affect any part of the GI tract, most commonly the ileum and colon, and is characterized by patchy, deep-seated inflammation that results in thickened bowel walls and ulceration. UC, on the other hand, is limited to the colon and involves continuous inflammation of the inner mucosal lining, often causing ulcers and bloody diarrhea. Symptoms of IBD vary but generally include abdominal pain, weight loss, fatigue, and malnutrition. Complications may involve bowel obstructions, fistula formation, and an increased risk of colorectal cancer^1-7.

IBD management primarily focuses on symptom control, maintaining remission, and improving quality of life through medication, lifestyle modifications, and, in severe cases, surgical interventions. Despite the uncertainty surrounding its exact cause, several risk factors have been identified, including genetic susceptibility, environmental influences such as diet and smoking, an overactive immune system, and imbalances in gut microbiota. However, not all individuals with risk factors develop IBD, highlighting the complexity of disease onset^3,4,8.

Indian traditional medicine, which emphasizes a holistic approach to health through natural remedies and preventive care, has been increasingly explored for its therapeutic potential in IBD. Herbal treatments derived from Indian medicinal plants are particularly valued for their ability to alleviate inflammation, promote gut health, and reduce symptoms with minimal side effects. Integrating these traditional remedies with modern medical treatments may offer a more comprehensive approach to managing IBD. This review examines recent advances in the use of Indian medicinal plants in IBD treatment^6-15.

Common Symptoms of IBD:

Both Crohn’s Disease (CD) and Ulcerative Colitis (UC) cause chronic inflammation of the GI tract, but they differ in location, disease progression, and symptom manifestation. CD can affect any part of the digestive tract, with the most common sites being the terminal ileum and ascending colon^16,17. UC, in contrast, is restricted to the colon and rectum. In CD, inflammation occurs in patches and can penetrate multiple layers of the intestinal wall, whereas in UC, the inflammation is continuous and limited to the mucosal lining^18,19.

CD often leads to complications such as fistulas, strictures, and malabsorption, which contribute to symptoms like diarrhea, abdominal pain, weight loss, and fatigue^20,21. Additionally, CD patients may experience oral ulcers, anal fissures, or fistulas. UC, on the other hand, is typically associated with symptoms such as frequent diarrhea, rectal bleeding, abdominal cramps, and an urgent need to defecate^22,23. Extraintestinal symptoms common to both conditions include joint pain, skin rashes, eye inflammation, and liver issues^22-24.

Indian Medicinal Plants in IBD Treatment:

Several Indian medicinal plants have shown potential in managing IBD by reducing inflammation, enhancing mucosal healing, and modulating the immune response.

1. Withaniasomnifera (L.) Dunal (Ashwagandha)

Family: Solanaceae²⁵

Plant Part Used in IBD: Root

Biological Source: Withaniasomnifera (L.) Dunal, commonly known as Ashwagandha, consists of the dried roots.

Mechanism in IBD:

· Anti-inflammatory: Withanolides inhibit inflammatory cytokines (TNF-α, IL-6, IL-1β), reducing intestinal inflammation.

· Antioxidant: Protects gut tissues from oxidative stress by neutralizing free radicals.

· Immunomodulatory: Balances immune function, preventing excessive immune activation.

· Stress reduction: As an adaptogen, it helps reduce stress-induced IBD flare-ups²⁶.

Uses in Treatment:

· Helps alleviate abdominal pain, diarrhea, and cramping.

· Promotes gut mucosal healing and reduces flare-up frequency²⁷.

Chemical Constituents:

· Withanolides (e.g., withaferin A, withanolide D) – Anti-inflammatory, immunomodulatory.

· Alkaloids (e.g., somniferine, anaferine) – Sedative, stress-relieving.

· Flavonoids, saponins, tannins – Antioxidant, gut-protective²⁷.

Figure 1. Structure of Withaferin A

2. Zingiber officinale Roscoe (Ginger)

Family: Zingiberaceae²⁸.

Plant Part Used in IBD: Rhizome

Biological Source: Zingiber officinale Roscoe, commonly known as Ginger. The rhizome is used medicinally.

Mechanism in IBD:

· Anti-inflammatory: Gingerol and shogaol inhibit TNF-α, IL-1β, IL-6, and COX-2, reducing inflammation.

· Antioxidant: Neutralizes free radicals, protecting intestinal cells.

· Immunomodulatory: Suppresses excessive immune response in IBD.

· Gut motility regulation: Improves digestion, reduces nausea^28,29.

Uses in Treatment:

· Reduces intestinal inflammation, cramping, and diarrhea.

· Supports mucosal healing and digestive health²⁸.

Chemical Constituents:

· Gingerols, shogaols: Anti-inflammatory, antioxidant.

· Zingerone, essential oils: Gut protective, antimicrobial²⁹.

Figure 2. Structure of Gingerols

3. Nigella sativa Linn. (Black Seed)

Family: Ranunculaceae³⁰.

Plant Part Used in IBD: Seeds

Biological Source: Nigella sativa Linn., commonly known as Black Seed or Black Cumin. The seeds are medicinally used.

Mechanism in IBD:

· Anti-inflammatory: Thymoquinone suppresses NF-κB, TNF-α, IL-1β, IL-6, reducing gut inflammation.

· Antioxidant: Prevents oxidative damage in intestinal cells.

· Immunomodulatory: Regulates immune response, preventing gut tissue damage.

· Antimicrobial: Helps maintain a balanced gut microbiome³¹.

Uses in Treatment:

· Reduces diarrhea, intestinal bleeding, and cramping.

· Supports mucosal healing and prevents relapses.

Chemical Constituents:

· Thymoquinone, nigellone: Anti-inflammatory, antioxidant.

· Alkaloids, flavonoids, saponins: Gut-protective, immune-modulating^30,31.

Figure 3. Structure of Thymoquinone

4. Curcuma longa L. (Turmeric)

Family: Zingiberaceae³²

Plant Part Used in IBD: Rhizome

Biological Source: Curcuma longa L., commonly known as Turmeric. The rhizome is medicinally significant.

Mechanism in IBD:

· Anti-inflammatory: Curcumin inhibits NF-κB, TNF-α, IL-1β, COX-2, reducing gut inflammation.

· Antioxidant: Neutralizes oxidative stress, protecting intestinal cells.

· Immunomodulatory: Modifies immune response to prevent flare-ups.

· Mucosal protective: Aids in intestinal lining repair.

Uses in Treatment:

· Treats ulcerative colitis, Crohn’s disease, and diarrhea.

· Helps maintain remission and reduce flare-ups.

Chemical Constituents:

· Curcumin, demethoxycurcumin, bisdemethoxycurcumin: Anti-inflammatory, antioxidant.

· Volatile oils (turmerone, atlantone): Antimicrobial, gut protective.

Figure 4. Structure of Curcumin

Uses in Treatment:

· Treats gastritis, ulcerative colitis, and gastric ulcers.

· Reduces cramping, diarrhea, and gut inflammation.

Chemical Constituents:

· Glycyrrhizin, flavonoids (liquiritin, isoliquiritigenin): Anti-inflammatory, antioxidant.

· Glabridin, polysaccharides: Gut protective, immune-modulating^33,34.

Figure 5. Structure of Glycyrrhizin

6. Moringa oleifera Lam. (Moringa)

Family: Moringaceae³⁵.

Plant Part Used in IBD: Leaves, seeds, and pods

Biological Source: Moringa oleifera Lam., commonly known as Moringa or Drumstick tree. The leaves, seeds, and pods are medicinally significant.

Mechanism in IBD:

· Anti-inflammatory: Flavonoids and phenolic acids inhibit TNF-α, IL-6, IL-1β, reducing inflammation.

· Antioxidant: Quercetin and chlorogenic acid protect gut tissues from oxidative stress.

· Immunomodulatory: Regulates immune balance, preventing IBD flare-ups.

· Mucosal protective: Supports intestinal lining repai³⁶.

Uses in Treatment:

· Treats gastritis, ulcerative colitis, and diarrhea.

· Reduces intestinal inflammation and promotes gut healing.

Chemical Constituents:

· Flavonoids (quercetin, kaempferol), phenolic acids (chlorogenic acid): Anti-inflammatory, antioxidant.

· Vitamins (A, C, E), glucosinolates: Gut protective, immune-modulating³⁶.

Figure 6. Structure of Quercetin

7. Aloe vera (L.) Burm.f.

Family: Asphodelaceae³⁷

Plant Part Used in IBD: Leaf gel

Biological Source: Aloe vera (L.) Burm.f., commonly known as Aloe vera. The gel from the leaves is medicinally used.

Mechanism in IBD:

· Anti-inflammatory: Aloe gel reduces levels of TNF-α, IL-6, and COX-2, alleviating gut inflammation.

· Mucosal protective: Enhances mucin production, promoting gut lining repair.

· Immunomodulatory: Modulates immune response, reducing excessive activation.

· Antioxidant: Neutralizes oxidative stress, protecting intestinal cells.

Uses in Treatment:

· Supports mucosal healing in ulcerative colitis.

· Reduces abdominal pain, cramping, and diarrhea.

Chemical Constituents:

· Aloin, emodin, barbaloin – Anti-inflammatory, laxative effects.

· Polysaccharides (acemannan, glucomannan) – Gut protective, immune-modulating.

· Anthraquinones – Antioxidant, antimicrobial²⁴.

Figure 7. Structure of Aloin

8. Boswellia serrata Roxb. (Indian Frankincense, Myrrh)

Family: Burseraceae³⁸.

Plant Part Used in IBD: Gum resin

Biological Source: Boswellia serrata Roxb., commonly known as Indian Frankincense. The gum resin is medicinally significant.

Mechanism in IBD:

· Anti-inflammatory: Boswellic acids inhibit 5-lipoxygenase (5-LOX), reducing leukotriene-mediated inflammation.

· Mucosal protective: Promotes intestinal healing and reduces permeability.

· Antioxidant: Protects gut tissues from oxidative stress^38,39.

Uses in Treatment:

· Effective in ulcerative colitis and Crohn’s disease.

· Reduces abdominal pain, diarrhea, and intestinal permeability.

Chemical Constituents:

· Boswellic acids (AKBA, KBA): Anti-inflammatory, gut healing.

· Essential oils (α-thujene, p-cymene): Antimicrobial, gut protective³⁹.

Figure 8. Structure of AKBA

9. Camellia sinensis (L.) Kuntze (Green Tea)

Family: Theaceae

Plant Part Used in IBD: Leaves⁴⁰

Biological Source: Camellia sinensis (L.) Kuntze, commonly known as Green Tea. The leaves are medicinally significant.⁴¹

Mechanism in IBD:

· Anti-inflammatory: Catechins inhibit NF-κB, TNF-α, and IL-6, reducing inflammation.

· Antioxidant: Scavenges free radicals, preventing oxidative damage to gut cells.

· Immunomodulatory: Modulates immune response, reducing excessive activation.⁴²

Uses in Treatment:

· Supports intestinal healing and reduces gut inflammation.⁴³

· Helps maintain remission in ulcerative colitis and Crohn’s disease.

Chemical Constituents:

· Catechins (EGCG, epicatechin, epigallocatechin): Antioxidant, anti-inflammatory.

· Theanine: Stress-reducing, gut-calming.

· Polyphenols: Gut-protective, antimicrobial.⁴⁴

Figure 9. Structure of Epigallocatechin

10. Cinnamomum verum J. Presl (Cinnamon)

Family: Lauraceae

Plant Part Used in IBD: Bark

Biological Source: Cinnamomum verum J. Presl, commonly known as Cinnamon. The bark is medicinally significant.^45-48

Mechanism in IBD:

· Anti-inflammatory: Cinnamaldehyde inhibits NF-κB, TNF-α, reducing inflammation.

· Antioxidant: Polyphenols protect gut cells from oxidative stress.

· Antimicrobial: Helps maintain gut microbiome balance.^49,50

Uses in Treatment:

· Reduces intestinal inflammation, bloating, and gut spasms.

· Supports mucosal healing and improves digestion⁵¹.

Chemical Constituents:

· Cinnamaldehyde, eugenol: Anti-inflammatory, antimicrobial.

· Polyphenols: Antioxidant, gut protective.

Figure 10. Structure of Cinnamaldehyde

Table 1. Herbal Agents with Therapeutic Potential in IBD

Sr. No	Botanical Name	Common Name	Part Used	Typical Dose Range	Major Bioactive Constituents	Pharmacological Role in IBD
1	Withania somnifera (L.) Dunal	Ashwagandha	Root	3–6 g/day (powder); 250–500 mg extract	Withanolides, alkaloids	Reduces gut inflammation, modulates immunity, relieves stress
2	Zingiber officinale Roscoe	Ginger	Rhizome	1–2 g/day (powder); 250 mg extract	Gingerols, shogaols, volatile oils	Anti-inflammatory, enhances digestion, antioxidant
3	Nigella sativa L.	Black Seed	Seeds	1–2 g/day (powder); 500 mg oil	Thymoquinone, nigellone, saponins	Regulates inflammation, protects mucosa, balances gut flora
4	Curcuma longa L.	Turmeric	Rhizome	1–3 g/day (powder); 500–1000 mg extract	Curcumin, demethoxycurcumin, turmerone	Suppresses inflammatory cytokines, supports mucosal repair
5	Glycyrrhiza glabra L.	Licorice	Root	1–3 g/day (powder); 400–800 mg extract	Glycyrrhizin, liquiritin, flavonoids	Soothes mucosa, reduces ulcers, inhibits inflammation
6	Moringa oleifera Lam.	Moringa	Leaves, seeds, pods	1–3 g/day (powder); up to 1500 mg extract	Quercetin, chlorogenic acid, vitamins A, C, E	Antioxidant protection, mucosal healing
7	Aloe vera (L.) Burm.f.	Aloe vera	Leaf gel	10–30 mL/day (juice/gel)	Aloin, emodin, acemannan	Promotes mucin secretion, soothes intestinal lining
8	Boswellia serrataRoxb.	Indian Frankincense	Gum resin	300–500 mg extract (standardized)	Boswellic acids (AKBA, KBA), essential oils	Inhibits leukotriene pathways, strengthens gut barrier
9	Camellia sinensis (L.) Kuntze	Green Tea	Leaves	2–3 cups/day (infusion) or 300 mg extract	Catechins (EGCG), theanine, polyphenols	Antioxidant, regulates immune response, anti-inflammatory
10	Cinnamomum verum J. Presl	Cinnamon	Bark	1–3 g/day (powder); 250–500 mg extract	Cinnamaldehyde, eugenol, polyphenols	Relieves intestinal spasms, supports digestion, antimicrobial

ABBREVIATIONS:

IBD – Inflammatory Bowel Disease; CD – Crohn’s Disease; UC – Ulcerative Colitis; GI – Gastrointestinal; TNF-α – Tumor Necrosis Factor-alpha; IL – Interleukin; NF-κB – Nuclear Factor kappa-light-chain-enhancer of activated B cells; COX-2 – Cyclooxygenase-2; AKBA – Acetyl-11-keto-β-boswellic acid; EGCG – Epigallocatechin gallate.

CONCLUSION:

Inflammatory Bowel Disease (IBD), which includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a persistent and relapsing condition of the gastrointestinal tract that poses significant therapeutic challenges. Conventional treatments focus on symptom relief and maintaining remission but are often associated with side effects and variable patient responses. In recent years, Indian medicinal plants have drawn attention as potential supportive therapies due to their rich content of bioactive compounds with anti-inflammatory, antioxidant, and immunomodulatory properties. Medicinal plants such as Withania somnifera, Zingiber officinale, Curcuma longa, and Boswellia serrata have shown encouraging effects in easing intestinal inflammation, promoting mucosal repair, and regulating immune function. These natural agents may serve as complementary options alongside standard medical treatments, offering a more holistic approach to disease management with fewer adverse effects. Nevertheless, current findings are mostly based on in vitro and animal studies, with limited clinical data available. To establish their therapeutic value, extensive research including clinical trials, dose standardization, and safety assessments is essential. Continued exploration in this field may contribute to the development of more effective and integrative treatment strategies for managing IBD.

CONFLICT OF INTEREST:

The authors have no conflicts of interest regarding this investigation.

ACKNOWLEDGMENTS:

We sincerely express our gratitude to Dr. Subhash University for their invaluable guidance and support in the completion of this review work.

REFERENCES:

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012; Jan 1; 142(1): 46–54.e42. doi: 10.1053/j.gastro.2011.10.010.

2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population based studies. Lancet. 2017; Oct 1; 390(10114): 2769–2778. doi: 10.1016/S0140-6736(17)32448-0.

3. Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE, et al. Population density and risk of inflammatory bowel disease: a prospective populationbased study in 13 countries or regions in AsiaPacific. Am J Gastroenterol. 2019 Jan 1; 114(1): 107–115. doi: 10.14309/ajg.0000000000000120.

4. Wilks S, Moxon W. Lectures on pathological anatomy. Longmans, Green; 1889.

5. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med. 1952 May 1;13(5):583–590.

6. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015 Apr 1;12(4):205–217. doi: 10.1038/nrgastro.2015.24.

7. Deshmukh R, Kumari S, Harwansh RK. Inflammatory Bowel Disease: A Snapshot of Current Knowledge. Res J Pharm Technol. 2020;13(4):1808. doi:10.5958/0974-360X.2020.00180.8

8. Singh NK. Ulcerative Colitis: A Comprehensive Review. Res J Pharm Technol. 2021;14(3):212. doi:10.5958/0974-360X.2021.00212.2

9. Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European evidence based consensus on diagnosis and management of ulcerative colitis Part 2: current management. J Crohn’s Colitis. 2017 Jul 1;11(7):769–784. doi: 10.1093/ecco-jcc/jjx108.

10. Sauk J. Diet and microbiome in inflammatory bowel diseases. In: Nutritional management of inflammatory bowel diseases. Springer; 2016. p. 3–16.

11. Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, et al. Consensus recommendations for patient centered therapy in mild to moderate ulcerative colitis: the i Support Therapy Access to Rapid Treatment (iSTART) approach. Intest Res. 2018 Oct 1;16(4):522.

12. Flamant M, Roblin X. Laboratory evaluation, including novel diagnostic markers. In: Crohn’s disease and ulcerative colitis. Springer; 2017. p. 233–242.

13. Cushing K, Higgins PD. Management of Crohn disease: a review. JAMA. 2021 Jan 1;325(1):69–80.

14. Di Paolo A, Luci G. Personalized medicine of monoclonal antibodies in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring, and beyond. Front Pharmacol. 2020 Dec 10;11:610806.

15. Jain P, Parkhe G. Alternative Colon Targeted Drug Delivery Approaches for the Treatment of Inflammatory Bowel Disease. Res J Pharm Technol. 2020;13(9):971. doi:10.5958/0974-360X.2020.00971.3

16. Zanke NA, Dhekane T, Ghonge AB, Zanke AA, Akotakar A. A Review of Ulcerative Colitis. Int J Technol. 2022;7(1):8. doi:10.52711/2231-3915.2022.00008

17. Pande S, Vashi J, Solanki A. Formulation and Characterization of Ileo-colonic Targeted Mucoadhesive Microspheres Containing Flurbiprofen for Treatment of Ulcerative Colitis. Res J Pharm Technol. 2020;13(6):600. doi:10.5958/0974-360X.2020.00600.9

18. Mahore JG, Deshpande NV, Trivedi RV, Shelar AS. Ulcerative Colitis: Treatment Updates. Res J Pharm Technol. 2020;13(6):615. doi:10.5958/0974-360X.2020.00615.0

19. Deshmukh R. Development and In‑Vitro Evaluation of Colon Specific Indomethacin Matrix Tablet for the Treatment of Inflammatory Bowel Disease. Res J Pharm Technol. 2021;14(4):422. doi:10.52711/0974-360X.2021.00422

20. Govind Hublikar R, Holla SN, Minnamreddigari C. Ameliorative Effect of Aqueous Extract of Carica papaya Linn. Leaves on Acetic Acid Induced Ulcerative Colitis in Male Albino Wistar Rats. Res J Pharm Technol. 2023;16(3):353. doi:10.52711/0974-360X.2023.00353

21. Ariharasivakumar G, Karthikaa T, Nongkhlaw R, Packialakshmi P. Evaluation of Leaf Extracts of Simarouba glauca on Experimentally Induced Inflammatory Bowel Diseases in Wistar Rats. Res J Pharm Technol. 2020;13(3):340. doi:10.5958/0974-360X.2020.00340.6

22. Chandra S, Das A, Roy T, Bose P, Paul S, Mukherjee L, et al. Emergent Strategy in Management of Inflammatory Bowel Disease: A Narrowed in on Novel Drugs. Res J Pharm Technol. 2021;14(3):321. doi:10.5958/0974-360X.2021.00321.8

23. Chandra S, Roy T, Bose P, Ghosh S, Paul S, Roychowdhury V, et al. Protective Effect of Colocasia esculenta on TNBS Induced Ulcerative Colitis in Mice. Res J Pharm Technol. 2022;15(1):63. doi:10.52711/0974-360X.2022.00063

24. Nugraha D, Putri NAS, Visuddho, Wungu CDK. Comparison of Bacterial Composition, Concentration, and Metabolism of Short Chain Fatty Acid in Inflammatory Bowel Disease: A Systematic Review. Res J Pharm Technol. 2021;14(10):1038. doi:10.52711/0974-360X.2021.01038

25. Popaniya HS, Vaja PN. A concise review on herbal immunity booster. Asian J Pharm Res. 2024 Mar 1;14(3):2024.

26. Chandran S, Patwardhan B. Withania somnifera (Ashwagandha): A promising remedy for IBD. J Ethnopharmacol. 2021 Oct 1;274:113734.

27. Singh N, et al. Ashwagandha (Withania somnifera): A systematic review of its therapeutic potential and mechanisms of action. Phytother Res. 2020 Apr 1;34(4):811–823.

28. Vaja PN, Popaniya HS. A Systematic Review on Medicinal Plant Species to treat Pharyngitis. Asian J Pharm Technol. 2024 Jul–Sep;14(3).

29. Bhatia S, et al. Zingiber officinale (Ginger): A promising anti-inflammatory agent for IBD. Phytother Res. 2020 Mar 1;34(3):456–465.

30. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005 Jan 1;5(13):1735–1740.

31. Gholamnezhad Z, et al. A review of the pharmacological effects of Nigella sativa and its active constituents. Phytother Res. 2016 Aug 1;30(8):1259–1269.

32. Popaniya HS, Vaja PN. A basic Review on herbal plants for Sunscreen preparation. Res J Topical Cosmet Sci. 2024 Dec 1;15(2):2024.

33. Liu J, et al. Glycyrrhizin: A potential drug against inflammatory bowel disease. Food Chem Toxicol. 2019 Feb 1;125:333–341.

34. Isbrucker RA, Burdock GA. Risk and safety assessment on the consumption of licorice root (Glycyrrhiza sp.), its extract, and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol. 2006 Jun 1;44(3):163–192.

35. Anwar F, et al. Moringa oleifera: A food plant with multiple medicinal uses. Phytother Res. 2007 Feb 1;21(2):104–107.

36. Vergara-Jimenez M, et al. Nutritional and therapeutic potential of Moringa oleifera leaves in improving the health and wellbeing of humans. Int J Mol Sci. 2017 Dec 1;18(12):2766.

37. Popaniya HS, Vaja PN. A Review on Herbal Components used for Polyherbal Facewash. Asian J Pharm Res. 2024 Mar 1;14(3):2024.

38. Holt PR, et al. Curcumin therapy in inflammatory bowel disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020 Mar 1;18(3):528–537.

39. Hanai H, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006 Jul 1;4(5):657–663.

40. Lynch WD, Hsu R. Ulcerative colitis. StatPearls. Treasure Island: StatPearls Publishing; 2022.

41. Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014 Apr 1;13(4–5):463–466.

42. Feuerstein JD, Cheifetz AS, editors. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clinic Proceedings. Elsevier; 2014.

43. Myrelid P, Landerholm K, Nordenvall C, Pinkney TD, Andersson RE. Appendectomy and the risk of colectomy in ulcerative colitis: a national cohort study. Am J Gastroenterol. 2017 Aug 1;112(8):1311–1319.

44. Parian A, Limketkai B, Koh J, Brant SR, Bitton A, Cho JH, et al. Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta analysis. Gut. 2017 Aug 1;66(8):1390–1397.

45. Vaja PN, Popaniya HS. The botanical breakthrough: herbal approaches to reversing alopecia. Asian J Pharm Res. 2024 Oct–Dec;14(4).

46. Vaja PN, Popaniya HS. Exploring the efficacy of herbal plants in nephrolithiasis: an in-depth review. Asian J Pharm Res. 2024 Jul–Sep;14(3).

47. Vaja PN, Borkhataria CH, Popaniya HS. A systematic review on medicinal plant species to treat pharyngitis. Asian J Pharm Technol. 2024 Jul–Sep;14(3).

48. Popaniya HS, Vaja PN. A concise review on herbal immunity booster. Asian J Pharm Res. 2024 Mar 1;14(3).

49. Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh K L, et al. World gastroenterology organization global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol. 2016 Oct 1;50(10):803–818.

50. Pandey VN, et al. Phytochemistry and pharmacology of Aegle marmelos. J Med Plants.

51. Singh B, Sahu P. Role of Aegle marmelos in IBD: A review. Pharmacogn Rev. 2023.

Received on 17.04.2025 Revised on 23.06.2025

Accepted on 06.08.2025 Published on 04.10.2025

Available online from October 10, 2025

Asian J. Res. Pharm. Sci. 2025; 15(4):381-387.

DOI: 10.52711/2231-5659.2025.00056

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.